Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Coramitug (Primary)
  • Indications Amyloidosis; Transthyretin-related hereditary amyloidosis
  • Focus Adverse reactions; First in man
  • Sponsors Prothena

    • Most Recent Events

    • 12 Nov 2024 According to a Prothena media release, Phase 1 clinical trial results for coramitug in patients with ATTR amyloidosis published in Amyloid , the official journal of the International Society of Amyloidosis.
    • 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
    • 18 Apr 2021 According to a Prothena media release, positive results from the Phase 1 study of PRX004 presented by Dr. Ole Suhr, as part of the Emerging Science Session at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top